Stay updated with breaking news from Marc Odrich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– LNZ100 selected as lead candidate – Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours – Rapid onset and long...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
TearSolutions, Inc. Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Lacripep™ - read this article along with other careers information, tips and advice on BioSpace